RESUMEN
PURPOSE: Intracavitary high-dose-rate (HDR) brachytherapy (BT) for cervical cancer involves multiple applicator insertions. Our study addresses whether customized three-dimensional plans generated for the first insertion (using computed tomography [CT] planning) can be applied to subsequent insertions without significant changes in dose distributions if identical applicators are used. METHODS AND MATERIALS: Twenty-seven patients were treated with external-beam radiotherapy, platinum-based chemotherapy, and HDR BT. Either tandem and ovoids (TO, n=12) or tandem and ring (TR, n=15) applicators were used, based on clinical indications. Postimplant CT scans were acquired and custom plans generated for each insertion. Dose parameters for organs at risk (OARs) from the second insertion were retrospectively compared to those that would have been delivered using the initial plan. RESULTS: Overall, we observed a significant increase (p<0.038) in dose to International Commission on Radiation Units and Measurement points and 2cm(3) volumes of bladder and rectum when a single plan was used. The sigmoid and small bowel exhibited a more variable increase in dose. Applicator-specific results revealed a significant increase (p<0.030) to dose points and volumes for the rectum and bladder for TR applicators. Conversely, dose values from the more flexible TO did not show any significant trend, exhibiting large interpatient variations. CONCLUSIONS: A duplication of planned dwell times and positions from one insertion to the next does not duplicate dose distributions in HDR cervix applications. A single plan used for an entire course of BT can result in significant increases to OAR doses for TR and unpredictable OAR doses for TO applicators. Treatment plans should be tailored for each insertion to reflect current applicator and anatomical geometry.
Asunto(s)
Braquiterapia/métodos , Dosis de Radiación , Traumatismos por Radiación/prevención & control , Radiografía Intervencional/métodos , Planificación de la Radioterapia Asistida por Computador/métodos , Neoplasias del Cuello Uterino/radioterapia , Quimioterapia Adyuvante , Terapia Combinada , Femenino , Humanos , Interpretación de Imagen Asistida por Computador , Imagenología Tridimensional , Radioisótopos de Iridio/uso terapéutico , Planificación de Atención al Paciente , Dosificación Radioterapéutica , Radioterapia Asistida por Computador , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Neoplasias del Cuello Uterino/tratamiento farmacológicoRESUMEN
PURPOSE: To promote efficient workflow for image-guided high-dose-rate (HDR) brachytherapy (BT) for cervix cancer by implementing intraoperative ultrasound (US) guidance for placement and optimization of intrauterine applicators. We sought to establish this as part of routine radiation oncology practice without radiology consultation. METHODS AND MATERIALS: Thirty-five consecutive insertions were performed in 21 women between July 2006 and March 2007. Cervical dilation, tandem selection and insertion were guided by transabdominal US. Final tandem position following vaginal applicator insertion was also confirmed by US. Computed tomography (CT) imaging was used for treatment planning and to assess perforation and applicator suitability for each patient anatomy. RESULTS: Intrauterine tandem insertion was successfully guided by US in the majority of procedures (34/35). CT imaging confirmed accurate placement within the uterine canal in each case, compared with a historic institutional perforation rate of 10%. Visualizing patient anatomy during insertion altered the selection of tandem length and angle in 49% of cases, resulting in improved applicator matching to anatomy. Average insertion time significantly decreased from 34 to 26 minutes (p=0.01). Requests for assistance from gynecologic surgical oncology declined from 38% to 5.7% of procedures. CONCLUSIONS: Intraoperative US guidance for cervix BT has been successfully implemented with staff and equipment from radiation oncology. Using US during every insertion has led to improved applicator selection and placement while decreasing procedure time and reducing out of department consultations. These changes have eliminated repeat insertions due to unfavorable applicator placement (as revealed on postoperative CT), thus improving department efficiency and quality of patient care.
Asunto(s)
Braquiterapia/métodos , Planificación de la Radioterapia Asistida por Computador/métodos , Ultrasonografía Intervencional , Neoplasias del Cuello Uterino/radioterapia , Braquiterapia/instrumentación , Diseño de Equipo/instrumentación , Diseño de Equipo/métodos , Femenino , Humanos , Estudios Prospectivos , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador/instrumentación , Tomografía Computarizada por Rayos X/instrumentación , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento , Neoplasias del Cuello Uterino/diagnóstico por imagenRESUMEN
PURPOSE: To report the long-term control and toxicity outcomes of patients with clinically localized prostate cancer, who underwent low-dose-rate prostate brachytherapy with magnetic resonance spectroscopic image (MRSI)-directed dose escalation to intraprostatic regions. METHODS AND MATERIALS: Forty-seven consecutive patients between May 2000 and December 2003 were analyzed retrospectively. Each patient underwent a preprocedural MRSI, and MRS-positive voxels suspicious for malignancy were identified. Intraoperative planning was used to determine the optimal seed distribution to deliver a standard prescription dose to the entire prostate, while escalating the dose to MRS-positive voxels to 150% of prescription. Each patient underwent transperineal implantation of radioactive seeds followed by same-day CT for postimplant dosimetry. RESULTS: The median prostate D90 (minimum dose received by 90% of the prostate) was 125.7% (interquartile range [IQR], 110.3-136.5%) of prescription. The median value for the MRS-positive mean dose was 229.9% (IQR, 200.0-251.9%). Median urethra D30 and rectal D30 values were 142.2% (137.5-168.2%) and 56.1% (40.1-63.4%), respectively. Median followup was 86.4 months (IQR, 49.8-117.6). The 10-year actuarial prostate-specific antigen relapse-free survival was 98% (95% confidence interval, 93-100%). Five patients (11%) experienced late Grade 3 urinary toxicity (e.g., urethral stricture), which improved after operative intervention. Four of these patients had dose-escalated voxels less than 1.0 cm from the urethra. CONCLUSIONS: Low-dose-rate brachytherapy with MRSI-directed dose escalation to suspicious intraprostatic regions exhibits excellent long-term biochemical control. Patients with dose-escalated voxels close to the urethra were at higher risk of late urinary stricture.
Asunto(s)
Braquiterapia/métodos , Espectroscopía de Resonancia Magnética , Neoplasias de la Próstata/radioterapia , Anciano , Braquiterapia/efectos adversos , Supervivencia sin Enfermedad , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Traumatismos por Radiación/etiología , Dosificación Radioterapéutica , Recto/efectos de la radiación , Estudios Retrospectivos , Factores de Tiempo , Uretra/efectos de la radiación , Estrechez Uretral/etiologíaRESUMEN
PURPOSE: To report our experience using high-dose-rate (HDR) brachytherapy with computed tomographic (CT) imaging for locally advanced cervix cancer, using available resources to optimize the treatment. METHODS AND MATERIALS: Fifty-seven women with cervix cancer were treated between September 2004 and March 2008. Patients received external radiotherapy, HDR brachytherapy (7 Gy x4) and concurrent chemotherapy. CT planning was done for each insertion. RESULTS: Median age was 53 years (range, 29-89 years); majority (49%) had International Federation of Gynecology and Obstetrics stage IIB. The median follow-up was 22.6 months. There were 4 patients who required laser coagulation for rectal bleeding, and one patient required hemicolectomy for sigmoid stricture. There was no grade 3 or 4 genitourinary toxicity. The Kaplan-Meier overall survival, relapse free, central pelvic and pelvic control at 3 years was 86%, 62%, 89%, and 83%, respectively. Pelvic control for tumors 2 to 5 cm was 95% and 84% for tumors greater than 5 cm. CONCLUSIONS: Our early experience confirms that CT-based HDR brachytherapy for cervix cancer achieves disease control comparable to other published series. At the same time, conformal avoidance of organs at risk allows for low rates of toxicity.
RESUMEN
BACKGROUND: To compare two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the setting of hypofractionated high-risk prostate cancer treatment. METHODS: 3DCRT and dIMRT/Helical Tomotherapy(HT) planning with 10 CT datasets was undertaken to deliver 68 Gy in 25 fractions (prostate) and simultaneously delivering 45 Gy in 25 fractions (pelvic lymph node targets) in a single phase. The paradigms of pelvic vessel targeting (iliac vessels with margin are used to target pelvic nodes) and conformal normal tissue avoidance (treated soft tissues of the pelvis while limiting dose to identified pelvic critical structures) were assessed compared to 3DCRT controls. Both dIMRT/HT and 3DCRT solutions were compared to each other using repeated measures ANOVA and post-hoc paired t-tests. RESULTS: When compared to conformal pelvic vessel targeting, conformal normal tissue avoidance delivered more homogenous PTV delivery (2/2 t-test comparisons; p < 0.001), similar nodal coverage (8/8 t-test comparisons; p = ns), higher and more homogenous pelvic tissue dose (6/6 t-test comparisons; p < 0.03), at the cost of slightly higher critical structure dose (Ddose, 1-3 Gy over 5/10 dose points; p < 0.03). The dIMRT/HT approaches were superior to 3DCRT in sparing organs at risk (22/24 t-test comparisons; p < 0.05). CONCLUSION: dIMRT/HT nodal and pelvic targeting is superior to 3DCRT in dose delivery and critical structure sparing in the setting of hypofractionation for high-risk prostate cancer. The pelvic targeting paradigm is a potential solution to deliver highly conformal pelvic radiation treatment in the setting of nodal location uncertainty in prostate cancer and other pelvic malignancies.